Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 21 Aug 2023

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

in Cancer Molecular Targets and Therapeutics

Chian-Wei Chen
Chien-Yu Lin
Jeng-Shiuan Tsai
Chia-Yin Lin
Chao-Chun Chang
Yi-Ting Yen
Yau-Lin Tseng
Po-Lan Su
Chien-Chung Lin

Frontiers in Oncology

doi 10.3389/fonc.2023.1238876

2,440 views
2 citations

Mini Review

Published on 17 Aug 2023

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

in Cancer Molecular Targets and Therapeutics

Hoda Pourhassan
Vaibhav Agrawal
Vinod Pullarkat
Ibrahim Aldoss

Frontiers in Oncology

doi 10.3389/fonc.2023.1237031

10,935 views
13 citations

Original Research

Published on 17 Aug 2023

Clinical outcomes after vascular reconstruction using synthetic grafts for limb salvage in patients with lower extremity sarcoma: a single-center retrospective experience

in Cancer Molecular Targets and Therapeutics

Chuanxi Zheng
Gang Xu
Wei Li
Xin Weng
Hongwei Yang
Zuhui Wang
Shiquan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1199556

1,389 views

Original Research

Published on 17 Aug 2023

Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells

in Cancer Molecular Targets and Therapeutics

Elnaz Salmani-Javan
Davoud Jafari-Gharabaghlou
Esat Bonabi
Nosratollah Zarghami

Frontiers in Oncology

doi 10.3389/fonc.2023.1193708

3,258 views
15 citations

Systematic Review

Published on 16 Aug 2023

Clinicopathological and prognostic value of epithelial cell adhesion molecule in solid tumours: a meta-analysis

in Cancer Molecular Targets and Therapeutics

Peiwen Ding
Panyu Chen
Jiqi Ouyang
Qiang Li
Shijie Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1242231

2,270 views
2 citations

Original Research

Published on 15 Aug 2023

Antitumor effect of anti-vascular therapy with STING agonist depends on the tumor microenvironment context

in Cancer Molecular Targets and Therapeutics

Justyna Czapla
Alina Drzyzga
Sybilla Matuszczak
Tomasz Cichoń
Marek Rusin
Magdalena Jarosz-Biej
Ewelina Pilny
Ryszard Smolarczyk

Frontiers in Oncology

doi 10.3389/fonc.2023.1249524

3,619 views
8 citations

Original Research

Published on 11 Aug 2023

Natural history of intraosseous low-grade chondroid lesions of the proximal humerus

in Cancer Molecular Targets and Therapeutics

Christopher M. LaPrade
Logan M. Andryk
Joshua L. Christensen
John C. Neilson
Adam N. Wooldridge
Donald A. Hackbarth
Manpreet Bedi
David M. King

Frontiers in Oncology

doi 10.3389/fonc.2023.1200286

5,111 views
4 citations

Case Report

Published on 11 Aug 2023

Case Report: Response to ALK-TKIs in a metastatic lung cancer patient with morphological heterogeneity and consistent molecular features

in Cancer Molecular Targets and Therapeutics

Yu Yang
Han Liu
Tao-hua Liu
Xi-run Zheng
Bin Wu
Dong-jing Zhou
Guang-juan Zheng
Xiao-shu Chai

Frontiers in Oncology

doi 10.3389/fonc.2023.1209799

2,088 views
1 citation

Review

Published on 08 Aug 2023

Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise

in Cancer Molecular Targets and Therapeutics

Genevieve M. Abd
Madison C. Laird
Jennifer C. Ku
Yong Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1227884

5,747 views
18 citations

Review

Published on 03 Aug 2023

Novel insights into biomarkers of progression in Desmoid tumor

in Cancer Molecular Targets and Therapeutics

Baiqi Liu
Zefang Sun
Rui Zhou
Dingcheng Shen
Shuai Zhu
Lu Chen
Gengwen Huang

Frontiers in Oncology

doi 10.3389/fonc.2023.1206800

2,801 views
2 citations

Review

Published on 03 Aug 2023

The integrated stress response in cancer progression: a force for plasticity and resistance

in Cancer Molecular Targets and Therapeutics

Caleb L. Lines
Morgan J. McGrath
Tanis Dorwart
Crystal S. Conn

Frontiers in Oncology

doi 10.3389/fonc.2023.1206561

12,018 views
28 citations

Original Research

Published on 01 Aug 2023

AI-powered discovery of a novel p53-Y220C reactivator

in Cancer Molecular Targets and Therapeutics

Shan Zhou
Dafei Chai
Xu Wang
Praveen Neeli
Xinfang Yu
Aram Davtyan
Ken Young
Yong Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1229696

11,881 views
8 citations

Correction

Published on 31 Jul 2023

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel

in Cancer Molecular Targets and Therapeutics

Mingyue Xia
Shuyan Wang
Yannan Qi
Kaili Long
Enjie Li
Lingfeng He
Feiyan Pan
Zhigang Guo
Zhigang Hu

Frontiers in Oncology

doi 10.3389/fonc.2023.1257404

1,298 views
1 citation

Original Research

Published on 28 Jul 2023

WR1065 conjugated to thiol-PEG polymers as novel anticancer prodrugs: broad spectrum efficacy, synergism, and drug resistance reversal

in Cancer Molecular Targets and Therapeutics

Dale M. Walker
Tsvetelina I. Lazarova
Steven W. Riesinger
Miriam C. Poirier
Terri Messier
Brian Cunniff
Vernon E. Walker

Frontiers in Oncology

doi 10.3389/fonc.2023.1212604

3,783 views
1 citation

Review

Published on 28 Jul 2023

The roles of phospholipase C-β related signals in the proliferation, metastasis and angiogenesis of malignant tumors, and the corresponding protective measures

in Cancer Molecular Targets and Therapeutics

Yu-Nuo Wu
Xing Su
Xue-Qin Wang
Na-Na Liu
Zhou-Wei Xu

Frontiers in Oncology

doi 10.3389/fonc.2023.1231875

4,391 views
5 citations

Case Report

Published on 27 Jul 2023

Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Dandan Wang
Fanhui Zhang
Wanli Feng
Jiarong Pan
Tianming Yuan

Frontiers in Oncology

doi 10.3389/fonc.2023.1206833

2,572 views
3 citations